---
title: "Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic impact on families"
description: "Formulary evidence on Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic impact on families. Topics: Employment and productivity after recurrence in patients and caregivers, Financial toxicity in patients and caregivers, Out-of-pocket expenses compared with other cancers, Out-of-pocket costs during survivorship in commercial claims, and 1 further topic. 5 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description/economic-impact-on-families"
published: "2026-11-15T21:46:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic impact on families

<a id="heading-2.2.1.8.3"></a>

## 2.2.1.8.3 Economic Impact of HPV-negative head and neck squamous cell carcinoma on Families

<a id="topic-2.2.1.8.3-1"></a>

### Employment and productivity after recurrence in patients and caregivers

> “Although these results did not significantly differ based on cancer type, the highest proportions of patients noting that recurrence affected employment had gastric cancer (68.4%), HN cancer (66.7%), or TNBC (57.1%).”
> “The greatest impacts on the work productivity score were reported for those caring for people with HN cancer (mean [SD] score: 6.5 [2.1]) and TNBC (6.1 [2.5]) and on the activity score for those caring for people with HN cancer (6.1 [1.8]).”
> “From pre- to post-first recurrence, the proportion of caregivers working full-time decreased significantly from 86.1% to 3.0%”

Source: [Aguiar-Ibáñez et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11792841/)

<a id="topic-2.2.1.8.3-2"></a>

### Financial toxicity in patients and caregivers

> “At diagnosis, the median COST score was 17 (range, 2-41), and 31 (48%) reported high FT by FDQ.”
> “Mixed-effects logistic modeling showed similar odds of high FT over time for patients and caregivers (odds ratio, 1.66; 95% CI, 0.11-273.14).”

Source: [Mady et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12163717/)

> “Patients reported a median COST score of 27 while caregivers reported a median COST score of 16. Approximately 25.9% of patients and 44.4% of caregivers reported high financial toxicity (COST < 17.5).”

Source: [Nguyen et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10116977/)

<a id="topic-2.2.1.8.3-3"></a>

### Out-of-pocket expenses compared with other cancers

> “Median annual medical expenses ($8384 vs $5978; difference, $2406; 95% CI, $795-$4017) and relative out-of-pocket expenses (3.93% vs 3.07%; difference, 0.86%; 95% CI, 0.06%-1.66%) were higher for patients with HNC than for patients with other cancers.”

Source: [Massa et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6439752/)

<a id="topic-2.2.1.8.3-4"></a>

### Out-of-pocket costs during survivorship in commercial claims

> “Throughout the survivorship period, median total and OOP costs were $372 per month and $31 per month higher than baseline costs, respectively, with variation in expenses by demographic information, health plan type, and oncologic variables.”

Source: [Massa et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9585466/)

<a id="topic-2.2.1.8.3-5"></a>

### Psychological burden of caregivers

> “Fifty studies (15 cohort studies, 35 cross-sectional studies), including 4289 informal caregivers, were included in the review.”
> “Findings from these studies indicated a high prevalence of clinically significant distress among HNC caregivers: anxiety symptoms meeting clinical thresholds affected 29% to 63% of participants, while clinically significant depression was reported in 10% to 39% of cases.”

Source: [Xie et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13447393/)

## Related pages
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Terms and abbreviations](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations.md)
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product information and disease description](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Clinical evidence](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic information and modeling report](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: References](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references.md)
